AbbVie vs. Merck: Key Considerations
ABBV vs MRK: The Numbers
Side by side on the figures we publish for both companies. Not a ranking and not a recommendation — the same metrics, read off the same source, on the same day.
| Metric | ABBVAbbVie Inc. | MRKMerck & Co. |
|---|---|---|
| MoonshotScore | 76 | 74 |
| Price | $254.98 | $144.71 |
| Change (1D) | +1.62% | -1.91% |
| Market cap | $450.5B | $357.4B |
| P/E ratio | 71.8 | 100.5 |
A dash means we hold no published figure for that company — not a zero. Full analysis: ABBV · MRK.
AbbVie (ABBV) and Merck (MRK): A Concise Comparison
“MoonshotScore rates a US-listed stock 0 to 100 — higher means stronger numbers. Most carry an older nine-factor score; the rest use five sector-relative pillars, re-ranked daily — common stocks and ADRs only. Funds, ETFs, warrants, units, SPACs, preferreds, and notes carry none. It is built for education and deeper due diligence, not financial advice.”
Questions worth resolving before acting on the screen
What are the primary factors to consider when comparing ABBV and MRK?
Investors often look at valuation metrics, dividend yields, and future growth prospects. The market capitalization can also be a key factor when comparing the size and stability of each company.
How do AbbVie and Merck differ in their approach to research and development?
Each company has its own strategic priorities, which can affect their pipelines and future revenue streams. Reviewing their respective pipelines offers insight into their forward-looking strategies.
What are the key risks associated with investing in pharmaceutical stocks like ABBV and MRK?
Risks include regulatory hurdles, patent expirations, and competition from other pharmaceutical companies. Investors should also monitor news about clinical trial results and FDA decisions.
How do I decide which stock is better for my portfolio?
Consider your investment goals, risk tolerance, and time horizon. Compare the financial metrics and consider how each company fits into your overall investment strategy.